Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.5M Buy
186,266
+3,612
+2% +$241K 1.21% 30
2026
Q1
$11.5M Buy
182,654
+6,201
+4% +$432K 1.2% 41
2025
Q4
$11.7M Buy
176,453
+8,667
+5% +$560K 1.3% 31
2025
Q3
$11.3K Buy
167,786
+399
+0.2% +$31.6K ﹤0.01% 138
2025
Q2
$14.6M Buy
+167,387
New +$13.1M 1.71% 17

Other funds holding DXCM

Isthmus Partners's DXCM Position: Q2 2026 in Review

Isthmus Partners increased its DexCom (DXCM) stake by 2% in Q2 2026, buying an estimated $241K and bringing the position to 186,266 shares worth $12.5M. The position accounts for 1.21% of the portfolio, ranked #30.

Isthmus Partners first reported a position in DXCM in Q2 2025 and has held it in 5 quarters since. The position peaked at $14.6M in Q2 2025. 224 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Isthmus Partners held 186,266 shares of DexCom worth $12.5M as of Q2 2026.
  • Isthmus Partners bought 3,612 DexCom shares in Q2 2026, an estimated $241K.
  • DexCom made up 1.21% of Isthmus Partners's portfolio in Q2 2026, its #30 holding.
  • Isthmus Partners first reported a position in DexCom in Q2 2025 and has held it in 5 quarters since.
  • Isthmus Partners's DexCom position peaked at $14.6M in Q2 2025.
  • 224 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Isthmus Partners's 13F filing for Q2 2026, filed 20 Jul 2026.